Guardian Pharmacy Services is scheduled to release its Q4 2025 earnings on March 11. Analysts forecast revenue of $389.15 million and EPS of $0.22, with full-year 2025 revenue at $1.44 billion and earnings per share of $0.67. Over the past 90 days, 2026 revenue estimates dipped from $1.45 billion to $1.44 billion while EPS forecasts rose from $0.85 to $0.87.

The company will present at the Oppenheimer Healthcare MedTech & Services Conference later this month, where executives are expected to outline growth strategy, service expansion and capital allocation priorities. This appearance provides investors direct access to management commentary ahead of the annual reporting cycle.

Four analysts set a one-year average price target of $35.00, ranging from $34.00 to $36.00, implying roughly 8.2% upside from current levels. Brokerages maintain an average buy rating of 1.5 on a 1-to-5 scale, while a proprietary valuation model signals potential downside risk.